$3.80
3.06% yesterday
Nasdaq, Nov 25, 10:16 pm CET
ISIN
US87583X1090
Symbol
TNGX

Tango Therapeutics Inc Stock price

$3.80
-2.13 35.92% 1M
-3.11 45.01% 6M
-6.10 61.62% YTD
-3.75 49.67% 1Y
-6.61 63.50% 3Y
-6.43 62.85% 5Y
-6.43 62.85% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.12 3.06%
ISIN
US87583X1090
Symbol
TNGX
Sector

Key metrics

Market capitalization $408.19m
Enterprise Value $152.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.52
P/S ratio (TTM) P/S ratio 9.41
P/B ratio (TTM) P/B ratio 1.78
Revenue growth (TTM) Revenue growth 15.67%
Revenue (TTM) Revenue $43.38m
EBIT (operating result TTM) EBIT $-139.70m
Free Cash Flow (TTM) Free Cash Flow $-123.18m
Cash position $293.28m
EPS (TTM) EPS $-1.17
P/E forward negative
P/S forward 8.87
EV/Sales forward 3.32
Short interest 15.58%
Show more

Is Tango Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Tango Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Tango Therapeutics Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Tango Therapeutics Inc forecast:

Buy
100%

Financial data from Tango Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
43 43
16% 16%
100%
- Direct Costs 2.50 2.50
50% 50%
6%
41 41
26% 26%
94%
- Selling and Administrative Expenses 37 37
52% 52%
85%
- Research and Development Expense 141 141
25% 25%
326%
-137 -137
31% 31%
-316%
- Depreciation and Amortization 2.50 2.50
50% 50%
6%
EBIT (Operating Income) EBIT -140 -140
27% 27%
-322%
Net Profit -123 -123
23% 23%
-284%

In millions USD.

Don't miss a Thing! We will send you all news about Tango Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tango Therapeutics Inc Stock News

Neutral
Business Wire
20 days ago
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the third quarter ended September 30, 2024, and provided business highlights. “We have made great progress with our PRMT5 development program, including positive data...
Neutral
Business Wire
20 days ago
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced an update on its PRMT5 program. Based on positive data from the dose escalation and early dose expansion cohorts of the TNG462 phase 1/2 clinical trial, the Company has selected TNG462 to mov...
Negative
Seeking Alpha
3 months ago
Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gil...
More Tango Therapeutics Inc News

Company Profile

Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Cambridge, MA.

Head office United States
CEO Barbara Weber
Employees 140
Founded 2017
Website www.tangotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today